Clinical trials: Intracutaneous Drug Delivery
Dermatitis, Allergic Contact
Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
The purpose of this study is to compare the effect and safety of rHuPH20 or placebo for the prevention and treatment of skin allergic reaction to nickel. The study drug and placebo will be administered by intradermal injection.
- Trial name
- NCT00928447
- Testing
- rHuPH20
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Halozyme Therapeutics
Diabetes
Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin Infusion
The primary objective of this study is to investigate if intradermal (in the skin) basal and bolus insulin delivery of a fast acting insulin analog (NovoRapid) as needed to adequately control the blood glucose for a subject with…
- Trial name
- NCT01557907
- Testing
- Subcutaneous delivery via Medtronic Quick-Set, Intradermal delivery via the BD Research Catheter Set
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Becton, Dickinson and Company
Poliomyelitis
Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly
The present study intends to investigate the use of fractional doses of sanofi pasteur's IMOVAX Polio injected intradermally. The primary objective will be to demonstrate the non-inferiority of fractional doses of IMOVAX Polio…
- Trial name
- NCT00604058
- Testing
- Inactivated Poliomyelitis vaccine (IMOVAX)
- Where
- Philippines
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Allergy
Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis
It is estimated that 36 million Americans suffer from seasonal allergies and that ragweed is the primary cause of autumn allergies, 87% of patients with ragweed allergy suffer rhinoconjunctivitis.
- Trial name
- NCT00878774
- Testing
- ToleroMune Ragweed
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Circassia Limited
Allergic Rhinitis, Allergy
Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen
Birch pollen allergic patients are currently treated by subcutaneous injections of pollen extracts either by standard allergen specific immunotherapy (SIT) or ultra-rush immunotherapy.
- Trial name
- AN003 (NCT01728519)
- Testing
- AllerT SC, AllerT ID
- Where
- Switzerland
- Volunteers
- 29 people
- Sponsor
- Anergis
Intracutaneous Drug Delivery
Site Selection for Intracutaneous Saline Delivery
The goal of this exploratory study is to select the optimal body site for intracutaneous delivery of 0.5 milliliters of saline from the FLUGEN 101.2 microneedle-based device.
- Trial name
- NCT01767324
- Testing
- Injection to deltoid, Injection to forearm, Injection to thigh
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Relapsing Remitting Multiple Sclerosis
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with relapsing forms of multiple sclerosis.
- Trial name
- NCT01097668
- Testing
- ATX-MS-1467
- Where
- 16 sites in Russia, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Apitope Technology (Bristol) Ltd.
Venezuelan Equine Encephalitis Virus Infection
Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers
The Phase I study will assess the basic safety, tolerability, and immunogenicity of a DNA-based Venezuelan equine encephalitis virus (VEEV)vaccine candidate delivered by electroporation .
- Trial name
- NCT01984983
- Testing
- Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Ichor Medical Systems Incorporated
Peanut Allergy
A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal or intramuscular injection in adults with peanut allergy.
- Trial name
- NCT02851277
- Testing
- ASP0892 Intradermal, ASP0892 Intramuscular
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Meningococcal Infections, Meningitis
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®
The objective of this trial is to study the administration of the Menomune vaccine given intradermally and low-dose subcutaneously versus standard subcutaneously.
- Trial name
- NCT00850603
- Testing
- Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acute Migraine
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
- Trial name
- Zotrip (NCT02745392)
- Testing
- ZP-Zolmitriptan
- Where
- 36 sites in United States
- Volunteers
- 365 people
- Sponsor
- Zosano Pharma Corporation
Graves Disease
ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
Phase 1 study to assess the safety and biological activity of ATX-GD-59 in patients with Graves Disease not currently treated with anti-thyroid therapy.
- Trial name
- NCT02973802
- Testing
- ATX-GD-59
- Where
- 8 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Apitope International NV
Allergic Rhinitis
A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device
This is a research study of a vaccine for allergy to Japanese Red Cedar. The vaccine is called CryJ2-DNA-LAMP Plasmid vaccine. This research study will determine how the vaccine is tolerated and how research participants respond…
- Trial name
- NCT02146781
- Testing
- CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Immunomic Therapeutics, Inc.
Rabies, Japanese Encephalitis
Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers
This study evaluated the safety and immunogenicity of rabies vaccine and Japanese encephalitis vaccine in toddlers. All children developed adequate immune responses.
- Conditions
- Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis
- Trial name
- NCT00694460
- Testing
- Three 1 mL doses of Rabies vaccine and two JE vaccine, Three 0.5 mL doses of Rabies vaccine and two JE vaccine, Three 0.1mL doses of Rabies Vaccine and two JE vaccine
- Where
- Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novartis
Allergy
Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis
Grass pollen allergens are universally recognised as a major cause of allergic diseases in humans and animals, including asthma, allergic rhinitis, conjunctivitis and dermatitis.
- Trial name
- NCT01166061
- Testing
- ToleroMune Grass
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Circassia Limited
Diabetes, Diabetes Mellitus
Biolinq External Interferent Protocol
The primary objective of the study is to evaluate the interference effect of acetaminophen (APAP) on the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System during a single in-clinic day on Day 3 of the sensor…
- Trial name
- NCT06560177
- Testing
- The Biolinq MicroArray Intradermal Continuous Glucose Biowearable System
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Biolinq Inc.
Peanut Allergy
A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.
- Trial name
- NCT03755713
- Testing
- ASP0892
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Colorectal Carcinoma
IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)
This study is being conducted in order determine whether IMA910 as single agent with GM-CSF as adjuvant following pre-treatment with low-dose cyclophosphamide is safe and shows sufficient anti-tumour effectiveness in patients…
- Trial name
- IMA910-101 (NCT00785122)
- Testing
- Endoxana, Leukine, IMA910, Endoxana, Leukine, IMA910, Aldara
- Where
- 41 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 92 people
- Sponsor
- Immatics Biotechnologies GmbH
Migraine
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine
This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity.
- Trial name
- ADAM (NCT03282227)
- Testing
- M207 Microneedle System
- Where
- 31 sites in United States
- Volunteers
- 342 people
- Sponsor
- Zosano Pharma Corporation
Shigellosis
Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
This Phase 1 clinical trial is aimed to evaluate the safety and immunogenicity of 3 doses of a candidate vaccine against Shigella sonnei (1790GAHB vaccine) when administered at different dosages by different routes…
- Trial name
- NCT02034500
- Testing
- S. sonnei 1790GAHB
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GSK Vaccines Institute For Global Health S.r.l.